Poisoning with the recreational drug paramethoxyamphetamine ("death")

---

• 1.
• Buchanan JF, Brown CR. "Designer drugs". A problem in clinicaltoxicology. Med Toxicol Adverse Drug Exp 1988; 3: 1-17.
• 2.
• Felgate HE, Felgate PD, James RA, et al. Recentparamethoxyamphetamine deaths. J Analyt Toxicol 1998; 22:169-172.
• 3.
• Milroy CM. Ten years of "ecstasy". J R Soc Med 1999; 92:68-71.
• 4.
• Cimbura G. PMA deaths in Ontario. CMAJ 1974; 110:1263-1267.
• 5.
• Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivativefatalities in South Australia -- is "Ecstasy" the culprit? Am JForensic Med Pathol 1998; 19: 261-265.
• 6.
• Byard RW, James RA, Gilbert JD, Felgate PD. Another PMA-relatedfatality in Adelaide. Med J Aust 1999; 170: 139-140.
• 7.
• Green AR, Cross AJ, Goodwin GM. Review of the pharmacology andclinical pharmacology of 3,4-methylenedioxymethamphetamine(MDMA or "Ecstasy"). Psychopharmacol 1995; 119: 247-260.
• 8.
• McCann UD, Slate SO, Ricaurte GA. Adverse reactions with3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"). DrugSafety 1996; 15: 107-115.
• 9.
• Rochester JA, Kirchner JT. Ecstasy(3,4-methylenedioxymethamphetamine): history, neurochemistry,and toxicology. J Am Board Family Pract 1999; 12: 137-142.
• 10.
• Steele TD, McCann UD, Ricaurte GA.3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"):pharmacology and toxicology in animals and humans.Addiction 1994; 89: 539-551.
• 11.
• Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet1992; 340: 384-387.
• 12.
• Ask AL, Fagervall I, Ross SB. Selective inhibition of monoamineoxidase in monoaminergic neurons in the rat brain. NaunynSchmiedebergs Arch Pharmacol 1983; 324: 79-87.
• 13.
• Stockley IH. Drug interactions. 4th ed. London: ThePharmaceutical Press; 1996.
• 14.
• Galloway G, Shulgin AT, Kornfeld H, Frederick SL. Amphetamine,not MDMA, is associated with intracranial hemorrhage. J AccidentEmerg Med 1995; 12: 231-232.